📗 Cite This Artifact
Huntington's Disease Investment Landscape
Investment Landscape: Huntington's Disease
Overview
Investment Landscape: Huntington's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Huntington's Disease research.
Last updated: 2026-03-22 03:00 PT
Pathway / Mechanism Diagram
Clinical Trial Pipeline
Total Clinical Trials: 285 Active Trials (Recruiting/Active): 66
Trial Phases
| Phase | Count |
|-------|-------|
| PHASE1 | 38 |
| PHASE1, PHASE2 | 18 |
| PHASE2 | 51 |
| PHASE2, PHASE3 | 6 |
| PHASE3 | 22 |
| PHASE4 | 3 |
| NA | 63 |
| Not Applicable | 78 |
Trial Status
| Status | Count |
|--------|-------|
| RECRUITING | 44 |
| ACTIVE_NOT_RECRUITING | 13 |
| NOT_YET_RECRUITING | 9 |
| COMPLETED | 157 |
| TERMINATED | 23 |
| WITHDRAWN | 3 |
Top Therapeutic Approaches
...
Investment Landscape: Huntington's Disease
Overview
Investment Landscape: Huntington's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Huntington's Disease research.
Last updated: 2026-03-22 03:00 PT
Pathway / Mechanism Diagram
Clinical Trial Pipeline
Total Clinical Trials: 285 Active Trials (Recruiting/Active): 66
Trial Phases
| Phase | Count |
|-------|-------|
| PHASE1 | 38 |
| PHASE1, PHASE2 | 18 |
| PHASE2 | 51 |
| PHASE2, PHASE3 | 6 |
| PHASE3 | 22 |
| PHASE4 | 3 |
| NA | 63 |
| Not Applicable | 78 |
Trial Status
| Status | Count |
|--------|-------|
| RECRUITING | 44 |
| ACTIVE_NOT_RECRUITING | 13 |
| NOT_YET_RECRUITING | 9 |
| COMPLETED | 157 |
| TERMINATED | 23 |
| WITHDRAWN | 3 |
Top Therapeutic Approaches
- genetic: 29 trials
- mitochondrial: 28 trials
- amyloid: 8 trials
- metabolic: 4 trials
- synaptic: 4 trials
- metal: 2 trials
- growth_factor: 2 trials
- neuroinflammation: 1 trials
Investment Context
Huntington's disease has 285 total clinical trials, making it one of the smallest neurodegenerative investment areas. The genetic certainty of HD makes it an attractive target, yet the limited Phase 3 portfolio (22 trials) indicates translational challenges. Recent gene-silencing successes offer hope for increased investment.
Key Investment Themes
- Gene Silencing: Antisense oligonucleotides and RNAi approaches
- Huntingtin Modification: Direct targeting of mutant huntingtin protein
- Symptomatic Management: Continued investment in motor and psychiatric symptoms
- Biomarkers: Development of disease progression markers
Emerging Investment Areas
The historic approval of gene-silencing therapies has transformed HD investment landscape. Small molecule HTT inhibitors offer oral delivery advantages over ASOs. Mutant huntingtin lowering through multiple mechanisms remains a dominant focus. Neuronal calcium dysregulation targeting voltage-gated calcium channels represents a promising symptomatic approach with disease-modifying potential.
Priority Research Gaps
Late-Stage Development Bottleneck
Only 7.7% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Recommended Priorities
Therapeutic Target Priorities
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
- genetic: 29 trials - Growing area
- mitochondrial: 28 trials - Growing area
- amyloid: 8 trials - Growing area
- metabolic: 4 trials - Growing area
- synaptic: 4 trials - Growing area
Investment Outlook
Near-Term Opportunities (1-3 Years)
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Medium-Term Opportunities (3-5 Years)
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Long-Term Vision (5-10 Years)
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Related Pages
- [Huntington's Disease](/diseases/huntingtons)
- [Gene Therapy](/therapeutics/gene-therapy)](/therapeutics)
- [Huntingtin Protein](/entities/huntingtin)](/entities)
- [Clinical Trials: Huntington's](/clinical-trials)
See Also
- [NeuroWiki Home](/home)](/home)
- [Investment Landscape Overview](/content/investment)
External Links
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [SEC Filings](https://www.sec.gov/edgar/searchedgar/companysearch)
- [Google Finance](https://www.google.com/finance)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | investment-huntingtons |
| kg_node_id | None |
| entity_type | investment |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-0d112be33025 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'investment-huntingtons'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-investment-huntingtons?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Huntington's Disease Investment Landscape](http://scidex.ai/artifact/wiki-investment-huntingtons)
http://scidex.ai/artifact/wiki-investment-huntingtons